CAN-2409 — Competitive Intelligence Brief

CAN-2409 (CAN-2409) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: T-cell engager. Area: Oncology.

phase 2 T-cell engager CD3 Oncology Biologic

Target snapshot

CAN-2409 (CAN-2409) — Candel Therapeutics, Inc.. CAN-2409 is a T-cell engager that targets the CD3 component of the T-cell receptor.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CAN-2409 TARGET	CAN-2409	Candel Therapeutics, Inc.	phase 2	T-cell engager	CD3
Epkinly	EPCORITAMAB	Genmab Us, Inc.	marketed	Bispecific CD20-directed CD3 T Cell Engager [EPC]	T-cell surface glycoprotein CD3	2023-01-01
ELRANATAMAB	ELRANATAMAB		marketed		BCMA, CD3	2023-01-01
Elrexfio	elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Elrexfio	Elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Talvey	TALQUETAMAB	Janssen Biotech	marketed		T-cell surface glycoprotein CD3	2023-01-01
Tzield	TEPLIZUMAB	Provention Bio Inc	marketed	CD3-directed Antibody [EPC]	T-cell surface glycoprotein CD3	2022-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (T-cell engager class)

1. Candel Therapeutics, Inc. · 1 drug in this class